Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340216 · ClinicalTrials.gov registry record · Phase 1
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
A Phase 1 study of Psoriasis, sponsored by Arcutis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 5
- Study locations
NCT07340216: Recruiting Phase 1 study of Psoriasis, sponsored by Arcutis Biotherapeutics.
NCT07340216 is a Phase 1 study of Psoriasis that is actively recruiting participants, run by Arcutis Biotherapeutics. The registered enrollment target is 16 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07340216, a Phase 1 study of Psoriasis, is actively recruiting participants, sponsored by Arcutis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
Primary Outcome
Assessment of steady-state trough plasma concentrations after 2 weeks of study drug administration.
Conditions Studied
Interventions
- DRUG ARQ-154 Foam 0.3%
Study Locations (5)
Arkansas
- Arcutis Clinical Study Site 106 - Bryant
Florida
- Arcutis Clinical Study Site 107 - Miami Lakes
Idaho
- Arcutis Clinical Study Site 108 - Meridian
Indiana
- Arcutis Clinical Study Site 105 - West Lafayette
Texas
- Arcutis Clinical Study Site 104 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT07340216 shows while recruiting
NCT07340216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ARQ-154 Foam 0.3% is the first listed.
NCT07340216 lists 5 locations in 5 states (Arkansas, Florida, Idaho).
Frequently Asked Questions
What is clinical trial NCT07340216 about?
NCT07340216 is a clinical study titled "Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis". This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
What is the current status of trial NCT07340216?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-12-15. Estimated completion is 2027-02.
What conditions does trial NCT07340216 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT07340216?
The interventions under investigation include: ARQ-154 Foam 0.3% (DRUG).
Who is sponsoring clinical trial NCT07340216?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07340216 being conducted?
This trial has 5 study locations across Arkansas, Florida, Idaho, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07340216's enrollment target sits among peer trials
16 115th of 125 higher than 9 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI